Dr. Viktoria Krey
About Dr. Viktoria Krey
Dr. Viktoria Krey is a Medical and Regulatory Affairs Manager at Invitris, specializing in bacteriophages as an alternative to antibiotics. She holds a Bachelor of Science and a Master of Science in Molecular Biotechnology, as well as a doctorate in Host Pathogen Interaction.
Work at Invitris
Dr. Viktoria Krey has served as the Medical and Regulatory Affairs Manager at Invitris since November 2020. In this role, she focuses on medical and regulatory affairs related to bacteriophages, which are being promoted as viable alternatives to antibiotics. Her work is based in Garching bei München, Bayern, Deutschland, where she collaborates with various stakeholders to advance the understanding and application of bacteriophage therapy.
Education and Expertise
Dr. Viktoria Krey holds a Bachelor of Science (B.Sc.) in Molecular Biotechnology from Technische Universität München, which she completed from 2003 to 2006. She furthered her education with a Master of Science (M.Sc.) in the same field from 2006 to 2008. Dr. Krey earned her Doctorate (Dr. rer. nat.) in Host Pathogen Interaction from Klinikum rechts der Isar, Technische Universität München, between 2008 and 2012. Additionally, she completed a project management program at the Max-Planck-Institute of Biochemistry in 2011.
Background
Prior to her current position at Invitris, Dr. Viktoria Krey worked as a Microbiologist and Project Manager at FreshDetect from 2014 to 2015. She also held the position of Postdoctoral Fellow and Junior Group Leader at ZIEL, Microbiology Department, Technische Universität München, from 2012 to 2014. Her extensive background in microbiology and biotechnology has equipped her with the skills necessary for her current role in medical and regulatory affairs.
Achievements
Since joining Invitris, Dr. Viktoria Krey has been actively involved in promoting bacteriophages as a promising alternative to antibiotics. Her work emphasizes the importance of regulatory compliance and medical oversight in the development and application of bacteriophage therapies. Her contributions to the field of microbiology and biotechnology are supported by her educational background and professional experiences.